Ofloxacin: clinical evaluation in urinary and respiratory infections.
40 patients with urinary tract (30 cases) or pulmonary infections (ten cases) caused by different agents were treated with ofloxacin in order to evaluate the efficacy and safety of this new quinolone derivative. Treatment was performed with a dose of 300 mg three times a day for nine to 26 days. Out of the 30 urinary tract infections, 22 were clinically and bacteriologically cured, six had a clinical improvement but the causative organism persisted, one suffered a reinfection with a different pathogen and one failed to respond. Clinical and bacteriological cure was achieved in eight of the ten pulmonary infections. The overall clinical response for the two groups of patients was 97% (cure and improvement): bacteriological cure was achieved in 75% of the patients treated. No serious side effects of ofloxacin therapy were observed in any of our patients.
Delia
S
S
De Simone
C
C
Vullo
V
V
Sorice
F
F
D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin; D010078:Oxazines / Q000627:therapeutic use*; D011014:Pneumonia / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000890:Anti-Infective Agents; D010078:Oxazines; D015242:Ofloxacin